<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60423">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944735</url>
  </required_header>
  <id_info>
    <org_study_id>CTX-4430-CF-001</org_study_id>
    <nct_id>NCT01944735</nct_id>
  </id_info>
  <brief_title>Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celtaxsys, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thermo Fisher Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Appledown Clinical Research Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Celtaxsys, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Ireland: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of multiple oral doses of
      CTX-4430 when administered to cystic fibrosis (CF) patients once-daily (QD) for 15 days.This
      study will include four dose levels. For each dose level, blood samples will be collected
      for exploratory PK and PD assay validation. In addition, sputum will be collected for
      exploratory biomarker analysis. Following multiple dose administration, pulmonary function
      and exploratory lung clearance index (LCI) measurements will be taken.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessment of the safety and tolerability of multiple oral doses of CTX-4430 when administered to cystic fibrosis (CF) patients once-daily (QD)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in clinical signs and symptoms of safety data that include physical examinations, ECGs, vital signs, pulse oximetry, pulmonary function (spirometry), clinical laboratory results, and adverse events which will be summarized descriptively and reported in tabular form.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CTX-4430</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Mannitol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX-4430</intervention_name>
    <description>Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 4 cohorts on days 1-15.</description>
    <arm_group_label>CTX-4430</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>excipient in capsules</description>
    <arm_group_label>CTX-4430</arm_group_label>
    <arm_group_label>Placebo + Mannitol</arm_group_label>
    <other_name>osmitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Repeat doses of placebo will be administered orally, once-daily, to patients in 4 cohorts on days 1-15</description>
    <arm_group_label>Placebo + Mannitol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or female, 18 to 55 years of age (inclusive) at the time of screening.

          2. Confirmed diagnosis of CF based on the following: positive sweat chloride or sodium
             value ≥ 60 mEq/L, and/or genotype with two identifiable mutations consistent with CF,
             accompanied by one or more clinical features consistent with the CF phenotype or a
             diagnosis of CF made by a specialist in this condition.

          3. In the judgment of the Principal Investigator (PI), the patient is medically stable
             with no change in symptoms, medication, or with clinical laboratory results that in
             PI opinion are compatible with the diagnosis of either CF or a complication thereof
             and are judged acceptable for inclusion.

          4. Body mass index (BMI) ≥ 17.0 (kg/m2).

          5. Non-tobacco/nicotine-containing product user for a minimum of 6 months prior to the
             first study drug administration.

          6. Forced Expiratory Volume (FEV1) of &gt;50% and &lt;90% of predicted at screening.

          7. Must agree to use adequate method of contraception.

        Exclusion Criteria:

          1. Patient has displayed any significant clinical/laboratory/radiological/spirometric
             sign of unstable or unexpectedly deteriorating respiratory disease within 30 days
             prior to the first study drug administration.

          2. History or presence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,
             neurological, or psychiatric disease that depart from the patient's usual baseline
             level of health as a patient with CF.

          3. Has a history of lung transplantation.

          4. History or presence of alcoholism or drug abuse within 2 years prior to the first
             study drug administration.

          5. Personal or family history of prolonged QT syndrome; or a QTc interval &gt;430 msec
             (males) or &gt;450 msec (females) using Bazett's formula (QTcB) or deemed clinically
             significant by the PI.

          6. Sitting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, unless
             deemed clinically insignificant by the PI.

          7. Pulse is higher than 100 b.p.m or lower than 50 b.p.m. unless deemed clinically
             insignificant by the PI.

          8. Failure to satisfy the PI of fitness to participate for any other reason.

          9. In the judgment of the PI, clinically significant hemoptysis (&gt;30 cc per episode)
             within the last 180 days.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Stuart Elborn, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University, Belfast</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsten Gill</last_name>
    <phone>+44 (0)28 9055 4049</phone>
    <email>kirsten.gill@celerion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Medicinces Evaluation Unit</name>
      <address>
        <city>Wythenshawe</city>
        <state>Manchester</state>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Horsley, MA MBChB MRCP PhD</last_name>
      <phone>44 (0) 161 2912046</phone>
      <email>alexander.horsley@manchester.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnston Stewart, MB, BSc, DRCOG, MFPM</last_name>
      <phone>+44 (0) 28 90 554040</phone>
      <phone_ext>4014</phone_ext>
      <email>johnston.stewart@celerion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Bilton, MD</last_name>
      <phone>44 (0)20 7351 8182</phone>
      <email>d.bilton@rbht.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>September 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
